BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome

Απλή σελίδα τεκμηρίου
dc.contributor.authorSaridaki, Z.en
dc.contributor.authorPapadatos-Pastos, D.en
dc.contributor.authorTzardi, M.en
dc.contributor.authorMavroudis, D.en
dc.contributor.authorBairaktari, E.en
dc.contributor.authorArvanity, H.en
dc.contributor.authorStathopoulos, E.en
dc.contributor.authorGeorgoulias, V.en
dc.contributor.authorSouglakos, J.en
dc.date.accessioned2015-11-24T19:32:21Z
dc.date.available2015-11-24T19:32:21Z
dc.identifier.issn1532-1827-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23402
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectColorectal Neoplasms/drug therapy/*genetics/mortality/pathologyen
dc.subjectCyclin D1/*metabolismen
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subject*Microsatellite Instabilityen
dc.subjectMiddle Ageden
dc.subject*Mutationen
dc.subjectNeoplasm Metastasisen
dc.subjectPrognosisen
dc.subjectProto-Oncogene Proteins B-raf/*geneticsen
dc.titleBRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcomeen
heal.abstractBACKGROUND: The significance of BRAF mutations, microsatelite instability (MSI) status and cyclin D1 expression in patients with metastatic colorectal cancer (mCRC) was evaluated. METHODS: Primary tumours from 144 patients treated for mCRC were assessed for BRAF (V600E) mutation, MSI status and cyclin D1. The data were correlated with progression-free survival (PFS) and overall survival (OS). RESULTS: BRAF mutations were detected in 10 (out of 22, 45%) patients with MSI-H tumours compared with 2 (out of 122, 1.6%) in those with microsatellite stable tumours (P<0.001). The presence of BRAF mutations was correlated with cyclin D1 overexpression (7 out of 26 patients, 58% vs 5 out of 118 patients, 14%; P=0.001). Patients with BRAF-mutated primary tumours had a significantly decreased PFS (2.7 vs 9.8 months; P<0.001) and median OS (14 vs 30 months; P<0.001) than patients with wild-type (wt) tumours. Patients with MSI-H and BRAF-mutated tumours experienced significantly lower PFS (3.1 vs 11.4 months; P=0.008) and OS (14.5 vs 35.5 months; P=0.004) than patients with MSI-H and BRAF wt tumours. Similarly, BRAF mutations and cyclin D1 overexpression were correlated with decreased PFS (3.1 vs 8.6 months; P=0.03) and OS (17.8 vs 39.2 months; P=0.01). CONCLUSION: BRAF V600E mutations are associated with MSI-H status and cyclin D1 overexpression and characterize a subgroup of patients with poor prognosis.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1038/sj.bjc.6605694-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20485284-
heal.identifier.secondaryhttp://www.nature.com/bjc/journal/v102/n12/pdf/6605694a.pdf-
heal.journalNameBr J Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2010-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Πρωτότυπος φάκελος/πακέτο

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
Saridaki-2010-BRAF mutations, micr.pdf
Μέγεθος:
432.36 KB
Μορφότυπο:
Adobe Portable Document Format
Κατεβάστε

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ